AbbVie Inc. (ABBV) key performance indicators and operating metrics (23 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Adjusted Diluted Earnings per Share Excluding Specified Items | 2.65 USD_per_share | FY2026-Q1 |
| Aesthetics Portfolio Net Revenues | 1.19B | FY2026-Q1 |
| Immunology Portfolio Net Revenues | 7.29B | FY2026-Q1 |
| Neuroscience Portfolio Net Revenues | 2.88B | FY2026-Q1 |
| Oncology Portfolio Net Revenues | 1.63B | FY2026-Q1 |
| Adjusted Gross Margin Ratio | 83.60 percent | FY2026-Q1 |
| Adjusted Operating Margin Ratio | 40.80 percent | FY2026-Q1 |
| Net Revenues | 15B | FY2026-Q1 |
| Botox Therapeutic Net Revenues | 1.01B | FY2026-Q1 |
| Imbruvica Net Revenues | 556M | FY2026-Q1 |
| Rinvoq Net Revenues | 2.12B | FY2026-Q1 |
| Skyrizi Net Revenues | 4.48B | FY2026-Q1 |
| Botox Cosmetic Net Revenues | 668M | FY2026-Q1 |
| Humira Net Revenues | 688M | FY2026-Q1 |
Back to ABBV overview · ABBV earnings · ABBV holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.